Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China

Abstract Background Though bictegravir/emtricitabine/tenofovir (BIC/FTC/TAF) have been regulatory approved and included in the National Reimbursement Drug List in China, due to the affordability concern, generic version of efavirenz + lamivudine + tenofovir (EFV + 3TC + TDF) is still recommended as...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Cao Jing, Tang Wei, Wang Ning, Zheng Fang, Xiao Gang, Wang Xingzhi, Zhou Guoqiang, Wang Min
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMC 2023-06-01
Saila:	BMC Infectious Diseases
Gaiak:	BIC/FTA/TAF EFV + TDF + 3TC Persistence Treatment discontinuation First-line therapy China
Sarrera elektronikoa:	https://doi.org/10.1186/s12879-023-08359-w
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!